Variability of Reaction Time as a Marker of Executive Function Impairments in Fibromyalgia

Table 1

Demographic and clinical data of the sample; statistics of the group comparison.

	FMS patients ()	Control group ()
Age in years ()			.-53	.60
Years of education ()			-1.57	.12
Body mass index ()			1.77	.080
Depression (, %)	22 (42.3)	2 (7.1)	10.72	.001
Anxiety disorder (, %)	25 (48.1)	5 (17.9)	7.09	.008
Antidepressant medication (, %)	27 (51.9)	2 (7.1)	15.79	<.001
Opioid medication (, %)	23 (44.2)	0 (0.0)	17.38	<.001
Non-opioid analgesic medication (, %)	45 (86.5)	6 (21.4)	33.39	<.001
Anxiolytic medication (, %)	35 (67.3)	7 (25)	13.06	<.001
Beck Depression Inventory ()			8.39	<.001
McGill Pain Questionnaire: sum score ()			7.35	<.001
McGill Pain Questionnaire: pain intensity ()			8.52	<.001

Notes. : mean; SD: standard deviation; : number of cases; : statistic of the test for the group comparison (78 degrees of freedom); : statistic of the chi-squared test for the group comparison; : value of the group comparison. Patients were using the following analgesic drugs: nonsteroidal anti-inflammatory drugs, 29 patients; paracetamol, 34 patients; metamizole, 7 patients; anticonvulsants, 10 patients; tramadol, 20 patients; and codeine, 4 patients. Thirty-six (69.2%) patients and twenty (62.5%) controls reported to be in the menopausal or premenopausal phase. Among the participants of reproductive age, the distribution of the menstrual phase was as follows: menstruation, 4 patients and 2 controls; follicular phase, 3 patients and 4 controls; ovulation phase, 3 patients and 1 control; and lutein phase, 6 patients and 5 controls.